A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2017
At a glance
- Drugs BGB A317 (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 27 Apr 2017 According to a BeiGene media release, Professor Jun Zhu of the Peking University Cancer Hospital is the lead principal investigator of this trial.
- 27 Apr 2017 New trial record
- 21 Apr 2017 According to a BeiGene media release, first patient has been dosed.